ClinicalTrials.gg
RecruitingNCT07322159Updated Nov 9, 2026

IASO206 in Patients With Relapsed/Refractory Multiple Myeloma

An Early Phase 1 interventional study of IASO206 injection in Relapsed/Refractory Multiple Myeloma (RRMM), sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 9, 2026Now RecruitingFirst site in China+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 40 studies in Multiple Myeloma by Institute of Hematology & Blood Diseases Hospital, China — 32 open to participants now, 35 under way, none of them phase 3. Multiple Myeloma · Institute of Hematology & Blood Diseases Hospital, China.

Planned enrollment
27th of 36
18 · median 24
Started
2026
with 15 others
Phase 1
13 of 40
10 open now
Primary completion
2026-12
later than 9 of 34 live
Registered
26th of 40
by date

Among the 40 studies in Multiple Myeloma by Institute of Hematology & Blood Diseases Hospital, China, this one is the 27th largest by planned enrollment of the 36 interventional ones that give a count, is one of 16 that started in 2026, is one of 13 in phase 1, reaches primary completion later than 9 of the 34 other live ones, and was the 26th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

32 of the 40 studies in Multiple Myeloma by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 32 open studies →

Where they have run

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Multiple Myeloma by Institute of Hematology & Blood Diseases Hospital, China, or all of them as a file.
02

Study summary

This study is an open-label, single-arm early exploratory clinical study, aiming to evaluate the safety, tolerability and preliminary efficacy of IASO206 Injection(In Vivo CAR-T) in Patients with Relapsed/Refractory Multiple Myeloma

03

Conditions studied

  • Relapsed/Refractory Multiple Myeloma (RRMM)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 75 years old, male or female;
  • Diagnosed with multiple myeloma (RRMM) according to IMWG criteria, and have received at least 2 including one proteasome inhibitor and one immunomodulator; with documented disease progression (based on examination data) during or within 12 months after the latest anti-myeloma treatment (subjects whose last-line treatment was CAR-T therapy are not required to have progression within 12 months);
  • Presence of during screening according to any of the following criteria:

    • Serum monoclonal protein (M-protein) level: ≥5 g/L f;
    • Urine M protein level ≥200 mg/24 hours;
    • Light chain multiple myeloma without measurable lesions in serum or urine: the affected serum free light chain ≥100 mg/L with abnormal serum κ/λ free light chain ratio;
  • BCMA expression on MM cells determined by flow cytometry or pathology immunohistochemistry;
  • score ≤ 2;
  • Expected survival time ≥12 weeks;
  • Subjects must have adequate organ function:
  • Hematology: (ANC) ≥ 1×10\^9/L (supportive treatment within 7 days before laboratory test is not allowed); Absolute lymphocyte count (ALC) )≥0.3×10\^9/L; ≥50×10\^9/L (blood transfusion support within 7 days before laboratory test is not allowed); ≥60 g/L (without red blood cell [RBC] transfusion within 7 days before laboratory test);

    • Liver function: (ALT) and aspartate aminotransferase (AST)≤1.5× (ULN); serum total ≤1.5×ULN;
    • Renal function: calculated according to Cockcroft-Gault formula≥ 40 ml/min.
    • Coagulation function: fibrinogen ≥1.0 g/L; ≤1.5×ULN, prothrombin time (PT)≤1.5×ULN;
    • Blood oxygen saturation>91%;
    • (LVEF) ≥50%;
  • Subjects and their spouses agree to use effective methods with tools or drugs from the time the subject signs the form until one year after administration;
  • Subjects must sign a written informed consent form approved by the ethics committee before initiating the screening process.

Exclusion criteria

Exclusion Criteria:

  • Patients with suspected or confirmed central nervous system involvement by plasma cell neoplasms;
  • Multiple myeloma patients with plasma cell leukemia;
  • Patients with amyloidosis;
  • Patients who have received hematopoietic stem cell transplantation (Auto-HSCT) within 12 weeks before enrollment, or have a history of allogeneic hematopoietic stem cell transplantation (Allo-HSCT);
  • Patients who have received previous BCMA-targeted therapy;
  • Patients who have received plasma cell-targeted cellular therapy within 3 months before the screening period, or in whom received cellular therapy products can still be detected in peripheral blood;
  • Patients who have received other anti-tumor treatments requires an appropriate :

    • Received Bendamustine, fludalabine or high-dose cyclophosphoyl within 9 months before enrollment,or;
    • Received Monoclonal antibody treatment for multiple myeloma within 21 days before enrollment, or;
    • Received cytotoxic chemotherapy or proteasome inhibitor treatment within 14 days before enrollment, or;
    • Received immunomodulatory treatment within 7 days before enrollment, or;
    • Received other anti-tumor treatments (including but not limited to experimental drugs) listed above within 14 days before enrollment or at least 5 half-lives (whichever is longer);
  • Patients requiring long-term use of therapeutic doses of during the study period (defined as prednisone or equivalent >20 mg/day), except for physiological replacement, topical, and inhaled use;
  • Severe heart diseases:including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure ( [NYHA] classification ≥ grade III), severe arrhythmia,hypertension that cannot be controlled by medication;
  • Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases;
  • Patient who needs chronic use of agents;
  • Patients with malignant tumors other than multiple myeloma within 5 years before screening, excluding fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and those after radical resection Ductal carcinoma in situ of breast and papillary thyroid carcinoma;
  • Patients with a history of solid organ transplantation;
  • Major surgery history within 2 weeks before entering the study, or scheduled surgery during the study period or within 2 weeks after the study treatment;
  • Serious uncontrolled infections during screening: Bacterial, viral, fungal, etc. infections;
  • Positive surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and detectable hepatitis B virus (HBV) DNA in peripheral blood; virus (HCV) antibody positive and peripheral blood hepatitis C virus ( HCV) RNA positive; (HIV) antibody positive; cytomegalovirus (CMV) DNA test positive; syphilis test positive;
  • Patients who have received inactivated vaccines within 4 weeks before enrollment;
  • Women who are pregnant or breastfeeding;
  • Patients with mental illness, consciousness disorder, or central nervous system diseases, including but not limited to epilepsy or a history of Parkinson's disease;
  • Known severe allergic reaction to IASO206 or its formulation components (such as tocilizumab);
  • Patients with unresolved non-hematological toxic reactions from previous treatments, which have not returned to baseline or ≤Grade 1 (except for alopecia and Grade 2 peripheral neuropathy);
  • Other situations considered unsuitable by the investigator.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Active comparator
    IASO206

    IASO206 will be administered in one infusion.

    Drug: IASO206 injection

Interventions

  • DrugIASO206 injection

    The third-generation self-inactivating lentiviral vector that carries a BCMA-targeted CAR.

06

What researchers measure

Primary outcomes

  1. The incidence and severity of adverse events(AEs)

    Cytokine release syndrome (CRS) and ICANS would be graded according to the ASTCT consensus. All other AEs would be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).

    Time frame: up to 2 years after IASO206 infusion

Secondary outcomes

  1. Overall response rate (ORR)

    The proportions of subjects achieving stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), and Partial Response (PR) after IASO206 infusion.

    Time frame: up to 2 years after IASO206 infusion

  2. Time to response (TTR)

    The time from the start of the drug infusion in subjects to the first occurrence of sCR, CR, VGPR, or PR.

    Time frame: up to 2 years after IASO206 infusion

  3. MRD negativity rate

    The proportion of subjects who achieve MRD-negativity after IASO206 infusion.

    Time frame: up to 2 years after IASO206 infusion

  4. Duration of response (DOR)

    The time from the first assessment of sCR or CR or VGPR or PR to the first assessment of disease progression or death from any cause.

    Time frame: up to 2 years after IASO206 infusion

  5. Progression-free survival (PFS)

    The time from the date IASO206 infusion to the date of first disease progression or death from any cause (whichever occurs first)

    Time frame: up to 2 years after IASO206 infusion

  6. Overall survival (OS)

    The time from the date of IASO206 infusion to the date of death from any reason.

    Time frame: up to 2 years after IASO206 infusion

  7. Pharmacodynamics(PD)

    The levels of cytokines (IL-6, serum ferritin, CRP) in peripheral blood at each time point,and lymphocyte subsets after IASO206 infusion.

    Time frame: up to 2 years after IASO206 infusion

  8. Pharmacokinetic Analysis(PK)

    Maximum concentration (Cmax) of IASO206 particle and CAR-T cells.

    Time frame: up to 24 month after IASO206 infusion

  9. Pharmacokinetic Analysis(PK)

    Time of maximum concentration (Tmax) of IASO206 particle and CAR-T cells.

    Time frame: up to 24 month after IASO206 infusion

  10. Pharmacokinetic Analysis(PK)

    Area under the concentration versus time curve: IASO206 particle AUC0-12d; CAR-T cell AUC0-28d,AUC0-90d,AUC0-180d,AUC0-last

    Time frame: up to 24 month after IASO206 infusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 201 non-industry phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 99. This study's planned 11 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Jan 7, 2026
StartActual
Jan 8, 2026
Primary completionEst.
Dec 15, 2026was Oct 2026
CompletionEst.
Oct 15, 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
1 site added — first site in China
Show site
  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences · Tianjin, China
Oct 27, 2026
Start date
Jan 15, 2026→Jan 8, 2026 (actual)
Oct 27, 2026
Primary completion
Oct 15, 2026→Dec 15, 2026
Oct 27, 2026
Enrollment
12→18
Nov 9, 2026
Show all 2 updates
  1. Nov 9, 2026
    Enrollment 12→18
    + 1 other change: verification date
  2. Oct 27, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences · Tianjin, China
    Start date Jan 15, 2026→Jan 8, 2026 (now actual)
    Primary completion Oct 15, 2026→Dec 15, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07322159
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Jan 8, 2026
Primary completion
Dec 15, 2026 (estimated)
Completion
Oct 15, 2028 (estimated)
Last update
Nov 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion